Directa Plus slumps on warning of administration risk unless funding talks succeed

Shares fell 17.5% to 7.01p after Directa Plus warned it could be placed into administration if it fails to secure fresh funding within weeks. The AIM-listed group said it is in advanced talks with an unnamed institutional investor for a funding facility of up to £2.5m to extend its cash runway, but warned there is no certainty the transaction will be concluded.

Analysis

Immediate implication is a classic liquidity-run dynamic: counterparties (R&D partners, Tier-2 composite suppliers and specialty coatings customers) will de-risk exposure within days, converting a funding scare into a revenue shock that can erase several quarters of projected cash flow. That means revenue recognition and receivable quality are the first leading indicators to watch — expect sharp sequential declines in reported orders and a rise in overdue payables over 1–6 weeks if funding does not materialize.

If the firm fails and assets are sold, the highest-value items are concentrated: proprietary dispersion recipes, grade-specific IP and finished specialty powders — these are easily portable into larger chemistry platforms. Acquirers (global specialty chemical groups or well-capitalized composites suppliers) can cherry-pick tech and customer lists, leaving unsecured creditors and minority equity with near-zero recovery; the likely outcome is significant concentration of “clean-room” graphene expertise inside larger players within 3–12 months.

Catalysts to watch: a confirmed cash facility or convertible line (days–weeks) will cap downside and reprice equity; formal supplier credit stoppage or an administrator appointment (days) marks near-total equity wipeout. Reversal is possible if a strategic partner offers non-dilutive, milestone-tied prepayment from a large OEM — that would re-establish order flow visibility and likely restore >50% of yesterday’s market cap within 1–3 months, but it is a low-probability event relative to hard-credit solutions.

Key Decisions for Investors

• Short Directa Plus (AIM:DCTA / OTC:DTPKF) equity size = small (0.25–0.5% NAV). Timeframe 2–8 weeks. Rationale: liquidity shock → likely >70% downside if administration proceeds; set stop at +35% above entry if a firm funding announcement is released. Target 0.5–2p-equivalent or total loss on equity if administration avoided.
• Structured credit play: offer a 6–9 month senior-secured bridge (fund-level bilateral) with 15–20% cash coupon + warrants (strike = 150–200% current price), capped facility size sized to our risk appetite. Timeframe 3–9 months. R/R: coupon income while retaining upside via warrants; downside is principal loss on administration but recovery value of IP/plant may salvage part of exposure.
• Pair trade to capture consolidation: short small-cap graphene peer(s) and go long a diversified specialty chemical acquirer (e.g., Cabot CBT or Solvay SOLB) — size 0.5% / 0.5% NAV. Timeframe 3–12 months. Rationale: negative sentiment will compress valuations of pure-plays while acquirers rerate on strategic optionality; expected asymmetric upside in acquirers vs large downside in illiquid peers.
• Event hedge: buy cheap, short-dated protective puts on any larger supplier with direct revenue exposure to Directa (if liquid) or establish small cash reserves to opportunistically buy IP/assets post-failure. Timeframe 1–3 months. R/R: limited cost for option or cash-on-hand versus high optionality if assets are fire-sold.